APOL1 kidney disease
Kidney disease linked to APOL1 gene variants.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 5, 2, 3, 6, 1.
New guidelines and consensus this year
All papers from the last 12 months
127 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- APOL1 and chronic kidney disease in pediatrics: a study from the Biorepository and Integrative Genomics InitiativePediatr Nephrol2026 NovPMID 42283832
- Update on APOL1 and chronic kidney diseases in childrenPediatr Nephrol2026 NovPMID 42249201Review
- Computational Drug Repurposing Reveals Lopinavir and Ritonavir as Potential Inhibitors of APOL Proteins for Combating Kidney and Neuropsychiatric DisordersCurr Drug Targets2026 Oct 13PMID 42872640
- Clinical and genetic risk factors for apolipoprotein L1-mediated chronic kidney disease in people of African ancestry with HIVCurr Opin Infect Dis2026 Oct 12PMID 42859850
- APOL1 Risk Genotypes and Sickle Cell Trait are Associated with Kidney Disease Progression in an Afro-Brazilian PopulationKidney3602026 Oct 8PMID 42848597
- Modifiers of Severity of Kidney Injury in Apolipoprotein L1 NephropathyJ Am Soc Nephrol2026 Oct 7PMID 42842312
- Differential regulation of basal and interferon-induced APOL1 gene expression in podocytesAm J Physiol Renal Physiol2026 Oct 1PMID 42734476
- Modeling podocytopathies with kidney organoidsNephrol Dial Transplant2026 Sep 30PMID 42012468Review
- HIV-associated nephropathy: A decade of clinical outcomes, global disparities and emerging promiseHIV Med2026 Sep 29PMID 42808260Review
- The APOL1 protective M1 modifier occurs exclusively with the KIK protein haplotype to suppress channel conductancemedRxiv2026 Sep 15PMID 42779842
More nephrology trends
All specialties →IgA nephropathy
IgA nephropathy and the new targeted treatments being studied.
Lupus nephritis
Kidney involvement in lupus and its newer treatments.
Key point: Lupus nephritis management is increasingly individualized, with expanding treatment options, combination therapy, and a trend toward lower corticosteroid doses.
Complement inhibitors in kidney disease
Iptacopan, avacopan and other complement inhibitors in glomerular disease.
Key point: Complement inhibitors had no overall effectiveness or safety advantage over plasma therapy in atypical hemolytic uremic syndrome, except lower relapse rates.
Home dialysis
Home haemodialysis and peritoneal dialysis.
Key point: Core interventions to reduce PD-related infections focus on surveillance, standardized staff and patient training, infection prevention assessments, and antimicrobial prophylaxis.
HIF-PH inhibitors for anaemia
Oral drugs such as roxadustat for anaemia of kidney disease.
Key point: HIF-PHIs such as roxadustat are reserved for non-dialysis CKD when erythropoiesis-stimulating agents are unsuitable, given potential risks and limited long-term data.
Race-free eGFR
Kidney function equations without a race coefficient.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
APOL1[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.